Form 4: Hims & Hers CFO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc. CFO Oluyemi Okupe reported exercising stock options and selling 11,595 Class A Common Stock shares under a pre-arranged 10b5-1 trading plan.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions involving the company's Class A Common Stock.
• The transactions occurred on October 3, 2025, pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Okupe exercised options to acquire 7,787 shares at an exercise price of $5.01 per share.
• Additionally, options were exercised to acquire 3,808 shares at an exercise price of $11.53 per share.
• A total of 11,595 shares of Class A Common Stock were sold at an average weighted price of $57.7173 per share, with individual sales ranging from $57.41 to $58.09.
• Following these transactions, Okupe directly owns 70,232 Class A Common Stock shares and indirectly owns 7,853 shares through the Oluyemi Okupe Separate Property Trust dtd 9-1-2021.
• Remaining derivative securities include 182,165 stock options exercisable at $5.01 and 59,976 stock options exercisable at $11.53.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns, indicating a planned financial management activity rather than a reaction to new, undisclosed negative information about the company.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-scheduled, non-discretionary sales, which can mitigate concerns about insider selling.
• The exercise prices of the options ($5.01 and $11.53) are significantly lower than the sale price ($57.7173), indicating a substantial profit for the insider from their equity compensation.

Negatives

• An insider, specifically the Chief Financial Officer, sold a significant number of shares (11,595 shares).

Risks

• Potential negative market perception due to insider selling, even if pre-arranged, as some investors may view it as a lack of confidence.

Future Outlook

The filing details pre-scheduled transactions under a Rule 10b5-1 plan, which may involve future exercises and sales as per the plan's terms, but no specific forward-looking guidance on company performance is provided.

Management Comments

• The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.

Industry Context

This Form 4 filing reports routine insider transactions for Hims & Hers Health, Inc.'s CFO. Such filings are common across publicly traded companies as executives manage their equity compensation and personal financial planning, often utilizing 10b5-1 plans to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May observe insider selling, which could be interpreted negatively, though the 10b5-1 plan provides a mitigating context, suggesting a pre-planned financial management activity rather than a reaction to new company-specific information.

Next Steps

• The Rule 10b5-1 trading plan may outline future scheduled transactions, but no specific company-related milestones or events are mentioned.

Key Dates

Keywords

Hims & Hers Health, HIMS, Oluyemi Okupe, CFO, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, Beneficial Ownership